Next Phase Newsletter

A venture capital firm based in the USA with a presence in China, has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. The firm seeks to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies globally, with a focus on those in USA, Europe, and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm is focused on early stage investment to support founders and their teams advance healthcare solutions.  The team originated at a global medical device company that has worked with researchers and physicians for more than 50 years to develop more effective therapeutic tools. The firm participates in pre-seed, seed and A rounds as a dedicated partner working closely with startups to advance technologies and build companies. Initial investment ranges from $250k-$1M. The firm has a global presence and is open to early-stage companies from around the world.

The firm’s investment focus is on 1) digital solutions to improving healthcare and 2) the development of life science tools to enable the production of advanced therapeutics.

The firm has no strict requirements for companies or management teams.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multi-billion AUM firm based in the USA is known for investing in technologies that change paradigms. The firm is currently investing out of a $1 billion venture fund for later stage investments and a $400 million for seed-stage investments. The firm has invested across a multitude of industries, including healthcare. Within healthcare, the firm is agnostic, choosing to select companies based on their potential impact. The firm will invest globally and generally prefer Seed and Series A opportunities for new investments.

While the firm is agnostic to sector and indication, the firm does have several areas of particularly high interest. Currently, the firm is interested in nucleic acid-based technologies and therapeutics, manufacturing and automation tools, and discovery tools. While the firm is open to any indication, the firm does prefer to invest in less crowded disease areas.

The firm places a strong emphasis on the team when investing.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The corporate venture arm of a senior living community invests strategically in companies that can enhance their services or the elderly population quality of life in general, including in healthcare. Within healthcare, the firm is willing to invest in digital health, medical devices and diagnostic/monitoring technologies, but will not invest in therapeutics. The firm generally invests in seed to series A, and will occasionally act as a company builder, co-founding a company around a promising technology. In an initial investment, the firm will generally invest no more than $.5M, but has the ability to invest in follow-on rounds. As a strategic investor, in addition to capital, the firm can employ their facilities for pilot programs, and will occasionally do so before investing. The firm is primarily interested in Israeli companies, but will invest globally.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The holding company of a large corporation is dedicated to fostering innovation across by investing in and partnering with strategic startups. The corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/Medical is one of the major focus areas of the firm. The corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines. The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data. Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm has a close, collaborative relationship with other business branches within the corporation, and can also present opportunities to the pharma branch, CRO, CDMO branches as appropriate.

The firm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. The venture group has a close relationship with all other business operations within the corporation and can actively support companies by leveraging these relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A transatlantic advisory and investment firm based in USA and Europe advises and invests exclusively in the life science space. The firm brings together early-stage US and EU based life science companies to bridge the Atlantic, gain scale and de-risk. It helps negotiate collaboration agreements and a road map towards a merger. The firm investment arm will invest $2-6M in the form of equity or convertible notes, for the most promising newly merged entities, by turning to a group of pledge investors. In the future, the firm is looking to raise a $100M transatlantic fund comprised of US and EU based sister funds that would invest jointly in the merged entities.

The firm seeks companies in all four life science sectors including therapeutics, medical devices, diagnostics, and digital health and is agnostic to both subsector and indication. The firm is open to preclinical and pre-prototype companies and all three classes of medical devices.

The firm’s whole focus is to bring together US and European teams, and starts the process by contacting companies looking to cross the Atlantic and establish a presence via a partnership. The firm looks for companies with a solid core team and the bandwidth to negotiate and build a transatlantic partnership that may evolve into a full-scale merger. The firm looks for companies in early stage, but not necessarily startups, since the core team is important. The firm also provides integration services to help the teams complement each other and work well together, a factor critical to the success of the merged entity. After engineering the merger, the firm will seek to take advantage of the significantly higher valuation to lead a new funding round. In these cases, the firm would seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Canada was founded by an experienced healthcare investment team, who has a successful track record of identifying, building, and growing life science companies. The firm recently launched a $200M (CAD) fund, through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.